Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tolebrutinib · PRN-2246, SAR-442168

Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Sanofi

N/A Most advanced trial
SNY Developer

What is Tolebrutinib?

Tolebrutinib is an orally bioavailable, brain-penetrant small molecule that selectively inhibits Bruton's tyrosine kinase (BTK), both peripherally and within the central nervous system. It blocks B-cell antigen receptor signaling and microglial inflammatory signaling. It is being studied in multiple sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PRN-2246, SAR-442168
Drug type
Small molecule
Targets
Bruton's tyrosine kinase (BTK)
Mechanism
Inhibitor of Bruton's tyrosine kinase (BTK)
Pathways
B-cell antigen receptor (BCR) signaling, microglial inflammatory signaling
Therapy area
Immunology, Neurology
Developer
Sanofi (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: N/A
UNII
8CZ82ZYY9X

Conditions studied

Multiple Sclerosis

Other drugs acting on BTK

More from Sanofi

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Tolebrutinib

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.